09:03 AM EST, 12/10/2024 (MT Newswires) -- Akoya Biosciences ( AKYA ) said Tuesday that it has signed an exclusive global license agreement with NeraCare to develop and commercialize the Immunoprint test on Akoya's multiplexed immunofluorescent platform.

The agreement grants Akoya rights to develop and market the test for clinical research, diagnostic development, or patient testing following regulatory approval, Akoya said.